"In the United States, Truvada is monopolized by the pharmaceutical giant Gilead, which charges between $1,600 and $2,000 a month for the treatment," Cooper writes. (Photo: Reuters)
Why Is the Government Allowing Its Own Drug Research to Be Monopolized for Profit?
The government is doing nothing to prevent outrageous price-gouging, which places a near-insurmountable barrier to getting a life-saving drug out to all who need it
How do we eradicate HIV/AIDS? One route is a vaccine, but so far that has proved a very difficult research problem. There is an ongoing clinical trial of one promising treatment in South Africa, but unlike the smallpox or polio vaccines, it appears to provide only moderate protection. Another is "pre-exposure prophylaxis," or PrEP -- drugs which prevent HIV infection if taken every day. One such treatment called emtricitabine/tenofovir (better known by its brand name Truvada) works very well for this, cutting the risk of infection by up to 93 percent.
"It's an object lesson in the dangers of allowing private companies to profiteer off government research."
But there is a problem. As The Washington Post reports, in the United States, Truvada is monopolized by the pharmaceutical giant Gilead, which charges between $1,600 and $2,000 a month for the treatment (the wholesale price is $1,414). Bizarrely, the studies proving Truvada works for PrEP were conducted and paid for almost entirely by the federal government (the Gates Foundation also helped). The Centers for Disease Control even holds a patent on this specific treatment.
Yet the government is doing nothing to prevent this outrageous price-gouging, which places a near-insurmountable barrier to getting the drug out to all who need it. It's an object lesson in the dangers of allowing private companies to profiteer off government research.
First, some background. Truvada was originally developed to treat people who already had HIV, as part of the usual suite of anti-retroviral medications to slow down the virus' progress. Two government-funded scientists proved it could be used to prevent transmission -- first Thomas Franks at the CDC, who demonstrated it worked with monkeys, then Robert Grant, who showed the same for humans with a grant from the National Institutes of Health. That work was completed around 2004.
Gilead immediately set about marketing and selling Truvada for PrEP, which brought in $3 billion last year and $36.2 billion since 2004. Yet because of the eye-watering price (and broader dysfunction in the American health-care system), only about 20 percent of the people who need the drug are getting it, and many who do have to navigate hellish bureaucracy to get access. The extreme cost also sucks money away from other priorities, particularly for cash-strapped state Medicaid programs.
Read the full article at The Week.
We are at a crossroads
This country and this world are at a monumental crossroads. In a few short weeks, US voters will have an opportunity to beat back the forces of fascism and confront the billionaires who are rigging the economy, our media system, and our democracy, making it increasingly impossible for ordinary people to get by. We’re not just talking about the election. We’re talking about what must be done once these fascist elements are vanquished from power. We need a bolder set of solutions than what either major party has so far been willing to offer and a working-class movement ready to fight like hell for it. Trump didn't emerge from nowhere. The conditions that fueled MAGA authoritarianism were created by decades of radical neoliberal economic policies and a corrupt political system dominated by corporate interests. They slashed taxes on the super-rich, promising that the benefits would trickle down. They said giveaways to the corporate titans would make life more affordable for the rest of us. It was all bullshit. And when a bitter, betrayed populace searches for someone to blame, right-wing demagogues have little trouble finding scapegoats. People know when they're being lied to, but you won't hear any of this from the corporate media. Only independent journalism—powered and funded by people who believe in building a better world—can deliver truly trustworthy daily news. Our Fall Campaign is underway, and we need your help. To power our newsroom through the rest of the year, we need to raise $125,000 by midnight on October 31. So if you share our vision, please contribute whatever you can to sustain our work. |
How do we eradicate HIV/AIDS? One route is a vaccine, but so far that has proved a very difficult research problem. There is an ongoing clinical trial of one promising treatment in South Africa, but unlike the smallpox or polio vaccines, it appears to provide only moderate protection. Another is "pre-exposure prophylaxis," or PrEP -- drugs which prevent HIV infection if taken every day. One such treatment called emtricitabine/tenofovir (better known by its brand name Truvada) works very well for this, cutting the risk of infection by up to 93 percent.
"It's an object lesson in the dangers of allowing private companies to profiteer off government research."
But there is a problem. As The Washington Post reports, in the United States, Truvada is monopolized by the pharmaceutical giant Gilead, which charges between $1,600 and $2,000 a month for the treatment (the wholesale price is $1,414). Bizarrely, the studies proving Truvada works for PrEP were conducted and paid for almost entirely by the federal government (the Gates Foundation also helped). The Centers for Disease Control even holds a patent on this specific treatment.
Yet the government is doing nothing to prevent this outrageous price-gouging, which places a near-insurmountable barrier to getting the drug out to all who need it. It's an object lesson in the dangers of allowing private companies to profiteer off government research.
First, some background. Truvada was originally developed to treat people who already had HIV, as part of the usual suite of anti-retroviral medications to slow down the virus' progress. Two government-funded scientists proved it could be used to prevent transmission -- first Thomas Franks at the CDC, who demonstrated it worked with monkeys, then Robert Grant, who showed the same for humans with a grant from the National Institutes of Health. That work was completed around 2004.
Gilead immediately set about marketing and selling Truvada for PrEP, which brought in $3 billion last year and $36.2 billion since 2004. Yet because of the eye-watering price (and broader dysfunction in the American health-care system), only about 20 percent of the people who need the drug are getting it, and many who do have to navigate hellish bureaucracy to get access. The extreme cost also sucks money away from other priorities, particularly for cash-strapped state Medicaid programs.
Read the full article at The Week.
How do we eradicate HIV/AIDS? One route is a vaccine, but so far that has proved a very difficult research problem. There is an ongoing clinical trial of one promising treatment in South Africa, but unlike the smallpox or polio vaccines, it appears to provide only moderate protection. Another is "pre-exposure prophylaxis," or PrEP -- drugs which prevent HIV infection if taken every day. One such treatment called emtricitabine/tenofovir (better known by its brand name Truvada) works very well for this, cutting the risk of infection by up to 93 percent.
"It's an object lesson in the dangers of allowing private companies to profiteer off government research."
But there is a problem. As The Washington Post reports, in the United States, Truvada is monopolized by the pharmaceutical giant Gilead, which charges between $1,600 and $2,000 a month for the treatment (the wholesale price is $1,414). Bizarrely, the studies proving Truvada works for PrEP were conducted and paid for almost entirely by the federal government (the Gates Foundation also helped). The Centers for Disease Control even holds a patent on this specific treatment.
Yet the government is doing nothing to prevent this outrageous price-gouging, which places a near-insurmountable barrier to getting the drug out to all who need it. It's an object lesson in the dangers of allowing private companies to profiteer off government research.
First, some background. Truvada was originally developed to treat people who already had HIV, as part of the usual suite of anti-retroviral medications to slow down the virus' progress. Two government-funded scientists proved it could be used to prevent transmission -- first Thomas Franks at the CDC, who demonstrated it worked with monkeys, then Robert Grant, who showed the same for humans with a grant from the National Institutes of Health. That work was completed around 2004.
Gilead immediately set about marketing and selling Truvada for PrEP, which brought in $3 billion last year and $36.2 billion since 2004. Yet because of the eye-watering price (and broader dysfunction in the American health-care system), only about 20 percent of the people who need the drug are getting it, and many who do have to navigate hellish bureaucracy to get access. The extreme cost also sucks money away from other priorities, particularly for cash-strapped state Medicaid programs.
Read the full article at The Week.